Osteoporosis

被引:33
作者
Brown, SA
Rosen, CJ
机构
[1] St Joseph Hosp, Maine Ctr Osteoporosis Res & Educ, Bangor, ME 04401 USA
[2] Univ N Carolina, Dept Med, Div Endocrinol, Chapel Hill, NC 27599 USA
[3] Jackson Lab, Bar Harbor, ME 04609 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1016/S0025-7125(03)00065-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteoporosis has a tremendous impact on the lives of many postmenopausal women. It is encouraging that effective treatments for this disease abound and the challenge is to ensure that those most in need of diagnosis or therapy obtain adequate care. Further research is expected to clarify the role of combination therapy or sequential use of different agents for the maximum benefit in fracture protection. There is an array of efficacious options to consider when diagnosing and treating osteoporosis so that patients and their caregivers can remain optimistic about the management of this chronic disease and prevention of future fractures.
引用
收藏
页码:1039 / +
页数:26
相关论文
共 115 条
[41]   Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women [J].
Downs, RW ;
Bell, NH ;
Ettinger, MP ;
Walsh, BW ;
Favus, MJ ;
Mako, B ;
Wang, LX ;
Smith, ME ;
Gormley, GJ ;
Melton, ME .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (05) :1783-1788
[42]   Bone strength at clinically relevant sites displays substantial heterogeneity and is best predicted from site-specific bone densitometry [J].
Eckstein, F ;
Lochmüller, EM ;
Lill, CA ;
Kuhn, V ;
Schneider, E ;
Delling, G ;
Müller, R .
JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (01) :162-171
[43]   Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -: Results from a 3-year randomized clinical trial [J].
Ettinger, B ;
Black, DM ;
Mitlak, BH ;
Knickerbocker, RK ;
Nickelsen, T ;
Genant, HK ;
Christiansen, C ;
Delmas, PD ;
Zanchetta, JR ;
Stakkestad, J ;
Glüer, CC ;
Krueger, K ;
Cohen, FJ ;
Eckert, S ;
Ensrud, KE ;
Avioli, LV ;
Lips, P ;
Cummings, SR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :637-645
[44]   Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: A randomized double-masked prospective study using three dose levels [J].
Fujita, T ;
Inoue, T ;
Morii, H ;
Morita, R ;
Norimatsu, H ;
Orimo, H ;
Takahashi, HE ;
Yamamoto, K ;
Fukunaga, M .
OSTEOPOROSIS INTERNATIONAL, 1999, 9 (04) :296-306
[45]   Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study [J].
Garnero, P ;
Sornay-Rendu, E ;
Claustrat, B ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (08) :1526-1536
[46]  
Garnero P, 1996, J BONE MINER RES, V11, P1531
[47]  
GILLESPIE LD, 2001, COCHRANE DB SYST REV, V3
[48]   Monitoring skeletal changes by radiological techniques [J].
Glüer, CC .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (11) :1952-1962
[49]   LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development [J].
Gong, YQ ;
Slee, RB ;
Fukai, N ;
Rawadi, G ;
Roman-Roman, S ;
Reginato, AM ;
Wang, HW ;
Cundy, T ;
Glorieux, FH ;
Lev, D ;
Zacharin, M ;
Oexle, K ;
Marcelino, J ;
Suwairi, W ;
Heeger, S ;
Sabatakos, G ;
Apte, S ;
Adkins, WN ;
Allgrove, J ;
Arslan-Kirchner, M ;
Batch, JA ;
Beighton, P ;
Black, GCM ;
Boles, RG ;
Boon, LM ;
Borrone, C ;
Brunner, HG ;
Carle, GF ;
Dallapiccola, B ;
De Paepe, A ;
Floege, B ;
Halfhide, ML ;
Hall, B ;
Hennekam, RC ;
Hirose, T ;
Jans, A ;
Jüppner, H ;
Kim, CA ;
Keppler-Noreuil, K ;
Kohlschuetter, A ;
LaCombe, D ;
Lambert, M ;
Lemyre, E ;
Letteboer, T ;
Peltonen, L ;
Ramesar, RS ;
Romanengo, M ;
Somer, H ;
Steichen-Gersdorf, E ;
Steinmann, B .
CELL, 2001, 107 (04) :513-523
[50]   Tolerability of once-weekly alendronate in patients with osteoporosis: A randomized, double-blind, placebo-controlled study [J].
Greenspan, S ;
Field-Munves, E ;
Tonino, R ;
Smith, M ;
Petruschke, R ;
Wang, LX ;
Yates, J ;
de Papp, AE ;
Palmisano, J .
MAYO CLINIC PROCEEDINGS, 2002, 77 (10) :1044-1052